SCHEMBL701944

SCHEMBL701944

CCOC(=O)OC1CCNC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.40
PKM P14618 1/20 0.40
SOAT1 P35610 1/20 0.39
SLC6A2 P23975 5/20 0.35
SLC6A4 P31645 5/20 0.35
SLC6A3 Q01959 4/20 0.35
CYP2D6 P10635 2/20 0.35
CHRM3 P20309 1/20 0.35
KCNH2 Q12809 1/20 0.35
SLC6A1 P30531 2/20 0.35
GABRA5 P31644 2/20 0.35
GABRB2 P47870 2/20 0.35
SLC6A12 P48065 2/20 0.35
SLC6A11 P48066 2/20 0.35
SLC6A13 Q9NSD5 2/20 0.35
GABRA1 P14867 1/20 0.35
GABRR1 P24046 1/20 0.35
GABRA4 P48169 1/20 0.35
F2 P00734 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9038793 0.90 ALDH1A1 (0.39) ALDH1A1MAPTPKMSOAT1CYP2D6
SCHEMBL6002610 0.90 ALDH1A1 (0.39) ALDH1A1MAPTPKMSOAT1CYP2D6
SCHEMBL1461712 0.89 ALDH1A1 (0.44) ALDH1A1MAPTPKMSOAT1SLC6A2
SCHEMBL4640870 0.80
SCHEMBL1078049 0.80 ALDH1A1 (0.57) ALDH1A1MAPTSOAT1
SCHEMBL13600289 0.79 HSP90AB1 (0.35) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL13600285 0.79 HSP90AB1 (0.35) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL5266355 0.79 HSP90AB1 (0.35) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL31249820 0.79 SLC6A1 (0.37) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL10696737 0.79 ALDH1A1 (0.41) ALDH1A1MAPTSOAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124766-B2 Inhibitors of diacylglycerol acyltransferase MADRIGAL PHARMACEUTICALS, INC. (US) 2012-02-28 US claimed
EP-2367817-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE Via Pharmaceuticals, Inc. (US) 2011-09-28 EP claimed
WO-2010065310-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE VIA PHARMACEUTICALS, INC (US) 2010-06-10 WO claimed
US-20100145047-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE MADRIGAL PHARMACEUTICALS, INC. 2010-06-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100145047-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE DGAT2, DGAT1, LCAT ALDH1A1 586/4885MAPT 3898/4885PKM 3119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.